S0819-Tumor-Annotations | Annotations for A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer

DOI: 10.7937/R0R8-BN93 | Data Citation Required | Analysis Result

Summary

This dataset contains image annotations derived from the NCI Clinical Trial “A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer”.  This dataset was generated as part of an NCI project to augment TCIA datasets with annotations that will improve their value for cancer researchers and AI developers.

Annotation Protocol

For each patient, all scans were reviewed to identify and annotate the clinically relevant time points and sequences/series. In a typical patient, all available time points were annotated. Every exam from the first available time point was annotated. One additional time point was annotated for each patient. The clinical data in the NCTN Archive was utilized to help determine the first evidence of disease progression. The first time point demonstrating disease progression was annotated. If that document was not accurate and did not demonstrate disease progression, then later time points were reviewed to assess for disease progression and the first time point demonstrating disease progression was annotated. If there was no evidence of disease progression on any time point, then the last available time point was annotated. Again, every exam from each chosen time point was annotated. For example, if there was a CT and a PET/CT, the PET was annotated along with one CT. If there was an MRI, that was annotated as well.

The following annotation rules were followed:

1. PERCIST criteria was followed for PET imaging. Specifically, the lesions estimated to have the most elevated SUVmax were annotated.
2. RECIST 1.1 was otherwise generally followed for any MR and CT imaging. A maximum of 5 lesions were annotated per patient scan (timepoint); no more than 2 per organ. The same 5 lesions were annotated at each time point. Lymph nodes were however annotated if > 1 cm in short axis. Other lesions were annotated if > 1 cm. If the primary lesion is < 1 cm, it was still annotated. If there was evidence of disease progression with new lesions then additional annotations were allowed to demonstrate that progression. A representative sample of the new lesions was annotated at the radiologist’s discretion.
3. Lesions were annotated in the axial plane. If no axial plane was available, lesions were annotated in the coronal plane.
4. MRIs were annotated using the T1-weighted post contrast sequence, fat saturated if available. If not available, T2-weighted sequences were utilized.
5. CTs were annotated using the axial post contrast series. If not available, the non contrast series was annotated.
6. PET/CTs were annotated on the CT and attenuation corrected PET images. However, if the post contrast CT was performed the same day as the PET/CT, the non contrast CT portion of the PET/CT was annotated.
7. Lesions were labeled separately.
8. The volume of each annotated lesion was calculated and reported in cubic centimeters [cc] in a dataset metadata report.
9. Seed points were automatically generated but reviewed by a radiologist.
10. A “negative” annotation was created for any exam without findings.

At each time point:

1. A seed point (kernel) was created for each segmented structure. The seed points for each segmentation are provided in a separate DICOM RTSS file.
2. SNOMED-CT “Anatomic Region Sequence” and “Segmented Property Category Code Sequence” and codes were inserted for all segmented structures.
3. “Tracking ID” and “Tracking UID” tags were inserted for each segmented structure to enable longitudinal lesion tracking.
4. Imaging time point codes were inserted to help identify each annotation in the context of the clinical trial assessment protocol.
   1. “Clinical Trial Time Point ID” was used to encode time point type using one of the following strings as applicable: “pre-dose” or “post-chemotherapy”
   2. Content Item in “Acquisition Context Sequence” was added containing “Time Point Type” using Concept Code Sequence (0040,A168) selected from:
      1. (255235001, SCT, “Pre-dose”)
      2. (262502001, SCT, “Post-chemotherapy”)

Important supplementary information and sample code

1. A spreadsheet containing key details about the annotations is available in the Data Access section below.
2. A Jupyter notebook demonstrating how to use the NBIA Data Retriever Command-Line Interface application and the REST API to access these data can be found in the Additional Resources section below.

Data Access

Version 2: Updated 2024/04/11

Added 1 patient

Collections Used In This Analysis Result

Additional Resources For This Dataset

• NCTN/NCORP Data Archive provides the Clinical Data files related to these subjects, and is also where you go to request access to the entire dataset
• Jupyter notebook demonstrating how to use the NBIA Data Retriever Command-Line Interface application and REST API (with authentication) to access these data
• Instructions for Visualizing these data in 3D Slicer

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier: